Monte Rosa Therapeutics, Inc. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 21st, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
EMPLOYMENT AGREEMENTEmployment Agreement • June 21st, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Filip Janku, MD, PhD (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated April 27, 2021, as amended May 4, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
Employment Agreement Dated as of 17 June, 2021 by and betweenEmployment Agreement • June 21st, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances)
